Empowering the Future of Vitamin K2 Science
The inaugural meeting in Lille, France, had Prof. Schurgers alongside the existing members—Hogne Vik, MD, PhD, MBA, and globally renowned K2 expert Katarzyna Maresz—welcomed the additional members who both add valuable experience and expertise that will support the mission to discover and confirm new benefits in the realm of vitamin K2:
- Stefanos Roumeliotis, MD, from AHEPA University Hospital (Greece), Department of Nephrology, specializes in chronic disease research and statistical analysis and is driving the MenaQ7® K2 VIKIPEDIA study.
- Sola Bahous, MD, PhD, MHPE, from Lebanese American University School of Medicine, offers expertise including arterial stiffness, pulse wave velocity, hypertension, and renal/kidney failure, and is immersed in the novel migraine study with MenaQ7® Vitamin K2.
The morning commenced with an engaging lecture by Prof. Schurgers, delving into the profound impact of Vitamin K2 on “Healthy Aging and the Vitamin K2 Effect.” This insightful session set the tone for a day filled with exploration and collaboration as an expanded team of experts shared their insights from various facets of Vitamin K2 research. It created an ideal setting to address the overarching theme of the meeting: “Exploring the Future of Vitamin K2.” With the committee now strengthened by leaders in K2 research, there is heightened anticipation on the journey to discover and confirm new benefits and applications of this foundational nutrient.
Shaping The Future of Vitamin K2 Through Scientific Collaboration
Gnosis is at the forefront of global Vitamin K2 research. In addition to the K2SAC, Gnosis actively collaborates with other research teams worldwide. This effort provides key insights from clinical studies, uncovering new indications and combinations for Vitamin K2.
Jean-Francois Jeanne, Gnosis Substantiation & Applications Team Manager, summarized the significance of the inaugural K2SAC meeting, stating, “We see our K2SAC galvanizing a worldwide network of esteemed researchers who will focus on identifying specific population needs for K2 and leading the clinical evidence to demonstrate K2’s beneficial use in those areas.”
This commitment underscores Gnosis’ dedication to advancing the understanding and applications of Vitamin K2 to support global health.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...